{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-105914","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.293217+00:00","generated_at":"2026-05-17T00:35:14.092873+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ocular Therapeutix Q3 net loss $69.4M; SOL-R hits 555 subjects; cash ~$790M with offering","bullets":["Net loss $(69.4)M ($0.38 loss per share) vs $(36.5)M loss in Q3 2024; revenue $14.5M, down 5.8% YoY.","SOL-R registrational trial in wet AMD achieved target randomization of 555 subjects; topline data on track for 1H 2027.","Cash balance $344.8M at Sep 30, plus ~$445M net proceeds from Oct equity offering providing runway into 2028.","HELIOS Phase 3 program for AXPAXLI in NPDR to start imminently using novel DRSS endpoint.","R&D expenses rose to $52.4M from $37.1M due to clinical trial costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-105914","json":"https://secwatch.observer/filing/0001104659-25-105914.json","markdown":"https://secwatch.observer/filing/0001104659-25-105914.md","text":"https://secwatch.observer/filing/0001104659-25-105914.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465925105914/0001104659-25-105914-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465925105914/tm2530039d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:35:14.092873+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}